CRISPR Therapeutics AG (CRSP) Change in Accured Expenses (2015 - 2026)

CRISPR Therapeutics AG has disclosed Change in Accured Expenses across 12 years of filings, most recently posting -$5.3 million for Q2 2026.

• In Q2 2026, Change in Accured Expenses rose 63.9% year-over-year to -$5.3 million; the TTM figure through Jun 2026 stood at -$1.7 million (up 90.26% YoY), while the FY2025 annual figure was $44.9 million, up 264.55% from the prior year.
• Change in Accured Expenses came in at -$5.3 million for Q2 2026 at CRISPR Therapeutics AG, up from -$13.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $43.0 million in Q1 2025 to a low of -$38.2 million in Q3 2024.
• Average Change in Accured Expenses over 5 years is -$877388.9, with a median of -$3.5 million recorded in 2022.
• Year-over-year, Change in Accured Expenses soared 2040.74% in 2022 and slumped 258.39% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$31.1 million in 2022, then soared by 70.44% to -$9.2 million in 2023, then gained by 14.59% to -$7.8 million in 2024, then jumped by 156.32% to $4.4 million in 2025, then slumped by 220.02% to -$5.3 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$5.3 million in Q2 2026, -$13.0 million in Q1 2026, and $4.4 million in Q4 2025.